StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) income statement

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)

Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –

ImmuCell Corp income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
40.3%
Operating margin
12.6%
Net margin
2.6%
Return on equity, FY2025
-3.8%

Financial strength

Current ratio
4.75
Debt to equity
0.26
Debt to assets
17.8%
Cash to current liabilities
199.7%

Valuation

P/E ratio
140.6
Price to sales
3.33
Price to book
3.26
Dividend yield
–

See a number that looks wrong?